Trial Testing Durvalumab Combinations in Stage III Non-Small Cell Lung Cancer
Researchers are comparing durvalumab in combination with oleclumab, monalizumab, or placebo in patients with non-small cell lung cancer.
Researchers are comparing durvalumab in combination with oleclumab, monalizumab, or placebo in patients with non-small cell lung cancer.
Researchers are comparing atezolizumab plus radiotherapy with atezolizumab alone in patients with small-cell lung cancer.
Researchers are comparing adagrasib with docetaxel in non-small cell lung cancer.
Researchers are comparing stereotactic radiosurgery with hippocampal-avoidant whole-brain radiotherapy plus memantine in patients with brain metastases from SCLC.
This phase 3 trial is designed to compare loncastuximab tesirine plus rituximab with standard immunochemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma.
This phase 3 trial is designed to test dociparstat sodium in combination with standard chemotherapy in newly diagnosed acute myeloid leukemia.
This phase 3 trial is designed to test nivolumab in combination with chemoimmunotherapy in newly diagnosed primary mediastinal B-cell lymphoma.
This phase 3 study is designed to compare venetoclax plus obinutuzumab with 1 of 2 rituximab-based regimens in previously untreated CLL.
The primary endpoint is MRD-negative complete response rate.
The primary outcome measures are overall response rate and the incidence of grade 4 or higher treatment-emergent adverse events.